ClinicalTrials.Veeva

Menu

Prevalence of the Metabolic Syndrome in SPR Taking Antipsychotics

S

Seoul National Hospital

Status

Unknown

Conditions

Schizophrenia
Metabolic Syndrome

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT00569504
snh001
PMSPSTA

Details and patient eligibility

About

The purpose of this study is to assess the cross-sectional prevalence of the metabolic syndrome in patients with schizophrenia taking antipsychotics.

Full description

Schizophrenic patients taking any kind of antipsychotics for at least 1 year at the Seoul National Hospital will be participated in this study.

we are planning to enroll approximately 1000 patients with schizophrenia.

For each subject

  • abdominal circumference
  • body mass index
  • lipid profile : TG, HDL-chlo, total chol
  • systolic/diastolic blood pressure
  • fasting blood glucose will be measured.

we will calculate the rates of patients who meet the criteria for the Metabolic syndrome.

  1. Abdominal obesity : absolute criteria

  2. 2 or more of followings

    1. Triglyceride ≥ 150mg/dL or ongoing treatment
    2. HDL-cholesterol < 40mg/dL (men) HDL-cholesterol < 50mg/dL (female) or ongoing treatment
    3. Hypertension 130mmHg ≥ systolic 85mmHg ≥ diastolic or ongoing treatment
    4. FBS ≥ 100mg/dL or previous diagnosis of type II DM

Enrollment

1,000 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients taking a same antipsychotics at least more than one year
  • schizophrenia or schizoaffective disorder

Exclusion criteria

  • none

Trial design

1,000 participants in 1 patient group

A, observatoin
Description:
inpatients and outpatients in Seoul National Hospital

Trial contacts and locations

1

Loading...

Central trial contact

Shi Hyun Kang, M.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems